Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Alkermes flagged new clinical data on alixorexton and LUMRYZ for disclosure at Sleep Europe 2026 in Maastricht on Oct. 20-23. Previously published phase 2 Vibrance-1 results for alixorexton in narcolepsy type 1 will be presented, alongside longer-term extension findings. Management framed the extension data as supporti
For best results when printing this announcement, please click on link below: Alkermes to Present New Data on Alixorexton and LUMRYZ(®) (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research — Data From Vibrance-1 Phase 2 Study Lancet Neurology Publication Evaluating Alixorexton in Na